GlobeNewswire
- Home
- PCT
as of 03-24-2026 3:54pm EST
$5.32
$0.57
-9.76%
PureCycle Technologies Inc is a Florida-based corporation focused on commercializing a patented dissolution process to physically separate the polymer from other plastics, color, and contaminants (the Technology), originally developed by The Procter & Gamble Company (P&G), for restoring waste polypropylene into resin with near-virgin characteristics, called PureFive resin. PureFive resin represents the family of recycled resin products produced, including ultra-pure resin and other grades used for compounding to meet customer specifications, which has similar properties and applicability for reuse as virgin polypropylene. It has a single operating segment, which encompasses integrated business activities related to the recycling of polypropylene into resins.
| Founded: | 2015 | Country: | United States |
| Employees: | 157 | City: | ORLANDO |
| Market Cap: | 1.6B | IPO Year: | N/A |
| Target Price: | $13.00 | AVG Volume (30 days): | 5.4M |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $5.12 - $17.37 | Next Earning Date: | 05-06-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 366.83% | Revenue Growth (next year): | 201.87% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
Latest PureCycle Technologies Inc. News
PCT Breaking Stock News: Dive into PCT Ticker-Specific Updates for Smart Investing
Motley Fool
Is PureCycle Technologies Stock a Buy or Sell After Shay Capital Dumped Shares Worth $3.2 Million?
📉
AI Sentiment
Negative
3/10
Compare PCT vs Leading Stocks
See how PCT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "PCT PureCycle Technologies Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.